ArticleCellular & molecular immunology2021
Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y
Open access · bronzeAbstract read
In one paragraph
Article in Cellular & molecular immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Association between Different Types of Tea Consumption and Risk of Gynecologic Cancer: A Meta-Analysis of Cohort Studies.Nutrients · 2023Pooled it
- Effect of ticagrelor and prasugrel on remote myocardial inflammation in patients with acute myocardial infarction with ST-elevation: a CMR T1 and T2 mapping study.The international journal of cardiovascular imaging · 2023Trial
- Target degradation of CASPASE-1 for alleviation of inflammation in sepsisActa pharmaceutica Sinica. B · 2026Article
- Respiratory, thoracic, and mediastinal adverse events associated with ticagrelor: A pharmacovigilance study based on FDA adverse event reporting system.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Association between clopidogrel use and improved survival in critically ill patients with acute kidney injury: insights from MIMIC-IV database.BMC nephrology · 2025Article
- Synthesis, characterization andNanoscale advances · 2025Article
- Effect of clonal hematopoiesis on plaque morphology and prognosis in patients with acute myocardial infarction.Genome medicine · 2025Article
- Cell death signaling and immune regulation: new perspectives on targeted therapy for sepsis.Cellular & molecular biology letters · 2025Review
- NLRP3 inflammasome: structure, mechanism, drug-induced organ toxicity, therapeutic strategies, and future perspectives.RSC medicinal chemistry · 2025Review
- Crosstalk between ferroptosis and NLRP3, a possible therapeutic target in experimentally-induced rheumatoid arthritis: role of P2Y12R inhibition in modulating P53/SLC7A11/ALOX15 signaling.Inflammopharmacology · 2025Article
- For Better or Worse: Type I Interferon Responses in Bacterial Infection.Pathogens (Basel, Switzerland) · 2025Review
- Targeting the NLRP3 inflammasome in kidney disease: molecular mechanisms, pathogenic roles, and emerging small-molecule therapeutics.Frontiers in immunology · 2025Review
- Platelets, inflammation, and purinergic receptors in chronic kidney disease.Kidney international · 2024Review
- GSNOR negatively regulates the NLRP3 inflammasome via S-nitrosation of MAPK14.Cellular & molecular immunology · 2024Article
- Crosslinked PVA-ACS omega · 2024Article
- Platelet P2YBritish journal of pharmacology · 2024Review
- Article
- Current concepts and novel targets for antiplatelet therapy.Nature reviews. Cardiology · 2023Review
- Inflammasomes in Atherosclerosis-From Pathophysiology to Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Artificial cells delivering itaconic acid induce anti-inflammatory memory-like macrophages to reverse acute liver failure and prevent reinjury.Cell reports. Medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 3 countries.
Bo Huang *Department of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yufeng Qian *Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Shujun Xie *Department of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xianhua YeDepartment of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Hanwen ChenDepartment of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0002-4871-8789
Zhifeng ChenDepartment of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Lihuan ZhangDepartment of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jinming XuDepartment of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Hu HuDepartment of Pathology and Pathophysiology, Zhejiang University School of Medicine, Hangzhou, China.
Shenglin MaDepartment of Oncology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Paul HérouxDepartment of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
Di WangInstitute of Immunology, Zhejiang University School of Medicine, Hangzhou, China.
Han-Ming ShenDepartment of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Yihua WuDepartment of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China. georgewu@zju.edu.cn.
Dajing XiaDepartment of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China. dxia@zju.edu.cn.
Women's Hospital, School of Medicine, Zhejiang University · CNHangzhou First People's Hospital · CNFirst Affiliated Hospital Zhejiang University · CNMcGill University · CANational University of Singapore · SGZhejiang University · CN
Funding
National Natural Science Foundation of China (National Science Foundation of China) 21976155National Natural Science Foundation of China (National Science Foundation of China) 31471297National Natural Science Foundation of China (National Science Foundation of China) 81773016
Abstract
Ticagrelor is the first reversibly binding oral P2Y
Indexed as
Signal TransductionAcute Coronary SyndromeAnimalsCARD Signaling Adaptor ProteinsChloridesDisease Models, AnimalHumansInflammasomesInflammationMacrophagesMiceMice, Inbred C57BLModels, BiologicalNLR Family, Pyrin Domain-Containing 3 ProteinProtein MultimerizationReceptors, Purinergic P2Y12CARD Signaling Adaptor ProteinsChloridesInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinPycard protein, mouseReceptors, Purinergic P2Y12TicagrelorASCChloride effluxNLRP3 inflammasomeP2Y12Ticagrelor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.